Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California. Show more

3115 Merryfield Row, San Diego, CA, 92121, United States

https://www.gossamerbio.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

99.14M

52 Wk Range

$0.33 - $3.87

Previous Close

$0.45

Open

$0.45

Volume

29,612,173

Day Range

$0.40 - $0.45

Enterprise Value

165.1M

Cash

180.2M

Avg Qtr Burn

-36.17M

Insider Ownership

4.16%

Institutional Own.

74.16%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Rare diseases, Pulmonary arterial hypertension, Lung disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seralutinib (GB002) Details Pulmonary hypertension associated with interstitial lung disease (PH-ILD)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB001 (Oral DP2 Antagonist) Details Asthma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.